We serve Chemical Name:(2S,3S,4E)-2-azido-3-O-(tert-butyldimethylsilyl)-4-octadecen-1,3-diol CAS:114299-64-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(2S,3S,4E)-2-azido-3-O-(tert-butyldimethylsilyl)-4-octadecen-1,3-diol
CAS.NO:114299-64-8
Synonyms:(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine
Molecular Formula:C24H49N3O2Si
Molecular Weight:439.75000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.21000
Exact Mass:439.35900
LogP:7.75806
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine Use and application,(2S,3R,4E)-2-Azido-3-(tert-butyldimethylsilyl)-erythro-sphingosine technical grade,usp/ep/jp grade.
Related News: Exploring biocatalysis options at the start of a project is a pragmatic operational strategy to achieve the right product, at the right quality, with exceptional efficiency. 3-O-benzyl-1-(8-fluorooctanoyl)-2-palmitoylglycerol manufacturers The vaccine has been through the ringer over safety worries before. In April, U.S. authorities halted its use and later tagged it with a warning over reports of rare blood clots occurring alongside bleeding in some recipients. 1-(2-chloro-1-methyl-5,6,8,9-tetrahydroimidazo[4′,5′:4,5]benzo[1,2-d]azepin-7(1H)-yl)-2,2,2-trifluoroethan-1-one suppliers This project is supported by the Irish Government through IDA Ireland. (4-amino-phenyl)-phosphonic acid monoethyl ester vendor & factory but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process.,Italian medical packaging firm Stevanato Group went public on the Big Board on July 16, raising $672 million and helping push up the fortune of the billionaire Stevanato family behind the company.
